NVN Liquidation Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2.3yrs
Durée moyenne du mandat des membres du conseil d'administration	7yrs

Mises à jour récentes de la gestion

Recent updates

PDG

NVN Liquidation n'a pas de PDG, ou nous n'avons pas de données sur eux.

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Carri Geer	Senior VP & CTO	4.9yrs	pas de données	pas de données
Tomoko Maeda-Chubachi	Chief Medical Officer	2.3yrs	pas de données	pas de données
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	pas de données	pas de données

2.3yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de 6LUA est considérée comme expérimentée (ancienneté moyenne 2.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Robert Keegan	Independent Director	7.8yrs	US$182.81k	0.15% € 7.8
Steven Skolsky	Independent Director	2.8yrs	US$162.19k	0.13% € 6.6
Diane Thiboutot	Member of Scientific Advisory Board - Acne Advisor	no data	pas de données	pas de données
Brian Berman	Member of Scientific Advisory Board -Antiviral Advisor	no data	pas de données	pas de données
W. Geer	Lead Independent Director	8.9yrs	US$202.90k	0.13% € 6.9
Eric Simpson	Member of Scientific Advisory Board - Inflammatory Skin Disease Advisor	no data	pas de données	pas de données
Machelle Sanders	Independent Director	6.3yrs	US$163.13k	0.090% € 4.6

7.0yrs

Durée moyenne de l'emploi

67.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 6LUA sont considérés comme expérimentés (ancienneté moyenne 7 ans).

NVN Liquidation Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

PDG

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen